Watch SNDX. Know when insiders buy.
One email the day a filing lands. Free.
SNDX
Syndax Pharmaceuticals Inc
17.87
−0.33 −1.81%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
64
WATCH · shorts 64
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.6BP/E —DIV YIELD —FCF YIELD —REV TTM $252.3M +222.7%NET INCOME −$220.8MNET DEBT $7.5M52W 13.11 – 25.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $72.8M | +91.8% | — | −$40M | −$49.4M | — | -0.55 | −$30.3M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $64.9M | +223.6% | — | −$34.2M | −$42.7M | — | -0.48 | −$50.3M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | $68.7M | +794.9% | — | −$62.5M | −$68M | — | -0.78 | −$69.5M | — | — | Feb 26 |
| Q3 2025 · Sep 30 | $45.9M | +267.0% | — | −$57.4M | −$60.7M | — | -0.70 | −$70.5M | — | — | Nov 3 |
| Q2 2025 · Jun 30 | $38M | +984.5% | — | −$69.4M | −$71.8M | — | -0.83 | −$87.8M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | $20M | — | — | −$83.8M | −$84.8M | — | -0.98 | −$95.2M | — | — | Aug 4 |
| Q4 2024 · Dec 31derived | $7.7M | — | — | −$96.4M | −$94.2M | — | -1.09 | −$57.4M | — | — | Feb 26 |
| Q3 2024 · Sep 30 | $12.5M | — | — | −$89.6M | −$84.1M | — | -0.98 | −$62.3M | — | — | Nov 3 |
| Q2 2024 · Jun 30 | $3.5M | — | — | −$74.2M | −$68.1M | — | -0.80 | −$71.6M | — | — | Nov 3 |
| Q1 2024 · Mar 31 | $0 | — | — | −$79.5M | −$72.4M | — | -0.85 | −$83.5M | — | — | Nov 3 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$77.9M | −$72.5M | — | -1.01 | −$41.3M | — | — | Feb 26 |
| Q3 2023 · Sep 30 | $0 | — | — | −$56.4M | −$51.1M | — | -0.73 | −$44.7M | — | — | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $172.4M | — | −$273.1M | −$285.4M | -165.6% | -3.29 | −$323M | $187K | −$323.2M | — | — |
| FY2024 · to Dec 31 | $23.7M | — | −$339.7M | −$318.8M | -1346.1% | -3.72 | −$274.9M | $0 | −$274.9M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$230M | −$209.4M | — | -2.98 | −$160.6M | $0 | −$160.6M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$151.8M | −$149.3M | — | -2.46 | −$133.7M | $0 | −$133.7M | — | — |
| FY2021 · to Dec 31 | $139.7M | — | $26.2M | $24.9M | 17.8% | 0.46 | $29.1M | $129K | $29M | — | — |
| FY2020 · to Dec 31 | $1.5M | — | −$71.4M | −$73.2M | -4822.5% | -1.87 | −$71.3M | $0 | −$71.3M | — | — |
Every number comes from Syndax Pharmaceuticals Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.